You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

44 search results for: symposium

expert video

Fibrosis and Type 2 Inflammation in PN

2 min

Dermatology

The pathophysiology of fibrosis, a key component of skin manifestations in prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023

expert video

PN and AD: Distinct Diseases with Underlying Type 2 Inflammation

1 min

Dermatology

Prurigo nodularis (PN) and atopic dermatitis (AD): Distinct diseases with underlying type 2 inflammation – highlights from the ADVENT symposium at AAD 2023.

expert video

Cutaneous Manifestations in AD & PN: Role of Type 2 Inflammation

23 min

Dermatology

Type 2 inflammation in the distinct cutaneous manifestations of atopic dermatitis and prurigo nodularis – a clip from the ADVENT symposium at AAD 2023.

expert video

AD and PN: Diagnosis and Impact on Quality of Life

1 min

Dermatology

Approaches to diagnosis and the multidimensional burden of atopic dermatitis and prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023.

expert video

Type 2 Inflammation and Chronic Pruritus in AD and PN

7 min

Dermatology

Highlights from the ADVENT symposium at AAD 2023 on the shared and unique roles of type 2 inflammation in atopic dermatitis and prurigo nodularis.

expert video

Unique and Overlapping Roles of Type 2 Cytokines in AD and PN

1 min

Dermatology

Explore the unique and shared roles of type 2 cytokines in atopic dermatitis and prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023.

expert video

Neuroimmune Axis and Pruritus in PN

2 min

Dermatology

Changes in nerve density and dysfunction of the neuroimmune axis drive pruritus in prurigo nodularis – Highlight from the ADVENT symposium at AAD 2023.

expert video

Presentation and Diagnosis of AD and PN

14 min

Dermatology

Presentation of atopic dermatitis and prurigo nodularis, and the impact of PN as an intensely pruritic disease – Clip from the ADVENT symposium at AAD 2023.

expert video

The Benefits of Early Intervention in AD: More Than Skin Deep – Q&A Session and Conclusion

13 min

Dermatology

This video from the March 2024 ADVENT AD symposium features the final panel discussion and conclusion. Dr. Eric Simpson, Dr. Katrina Abuabara and Dr. Lawrence Eichenfield discuss topics related to early intervention in AD and the impact of the cumulative disease burden that may manifest as atopic or non-atopic, systemic comorbidities. The faculty also field several questions submitted by the audience. Dr. Simpson concludes the panel discussion with a brief overview of the symposium.

expert video

Long-term Impacts of AD and the Potential Benefit of Early Intervention

2 min

Dermatology

In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the potential importance of early intervention in pediatric patients, and how addressing AD at an early stage may stop the clock on associated systemic comorbidities in the long term.

expert video

Inflamm-aging: Systemic Inflammation and Frailty in Older Adults

2 min

Dermatology

In this highlight video from the March 2024 AD symposium, Dr. Katrina Abuabara discusses the concept of inflamm-aging in older adult patients. She explains how the term is defined through measures of systemic inflammatory markers and how immunosenescence can contribute to systemic comorbidities in older adults with AD.

expert video

Is Pediatric AD Linked to Other Allergic Diseases?

2 min

Dermatology

In this highlight video from the March 2024 AD symposium, Dr. Lawrence Eichenfield discusses the relationship between skin barrier dysfunction and the potential for increased risk of allergic sensitization. He goes on to discuss the high proportion of pediatric patients with AD who exhibit at least 1 atopic comorbidity.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: United StatesChange country/region